RED TERAV - Investigadores

Investigadores

Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Inmunoterapia Celular (células CAR)

Terapia de células somáticas y medicina regenerativa

Desarrollos Tecnológicos y Terapéuticos

Investigadores
Publicaciones

FERMÍN SÁNCHEZ-GUIJO MARTÍN

Investigador principal

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Almudena Navarro Bailón

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Eva María Villarón Ríos

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

JUAN FRANCISCO BLANCO BLANCO

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

LUCIA LOPEZ CORRAL

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Manuel Adolfo Sánchez Martín

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

María Díez Campelo

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Maria-Victoria Mateos Manteca

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Miriam López Parra

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Sandra Muntión Olave

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Silvia Preciado Pérez

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Susana Martín Domínguez

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Biomédica de Salamanca (IBSAL). Salamanca.

Rodriguez-Sevilla J.J., Ganan-Gomez I., Ma F., Chien K., Del Rey M., Loghavi S., Montalban-Bravo G., Adema V., Wildeman B., Kanagal-Shamanna R., Bazinet A., Chifotides H.T., Thongon N., Calvo X., Hernández-Rivas J.M., Díez-Campelo M., Garcia-Manero G., Colla S.. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nature Communications. December 2024. DOI: 10.1038/s41467-024-46424-3.

Impacto: 16.6. Cuartil: Q1 (1er decil)

Dopeso H., Rodrigues P., Cartón-García F., Macaya I., Bilic J., Anguita E., Jing L., Brotons B., Vivancos N., Beà L., Sánchez-Martín M., Landolfi S., Hernandez-Losa J., Ramon y Cajal S., Nieto R., Vicario M., Farre R., Schwartz S., van Ijzendoorn S.C.D., Kobayashi K., Martinez-Barriocanal Á., Arango D.. RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis. iScience. 19 April 2024. DOI: 10.1016/j.isci.2024.109400.

Impacto: 5.8. Cuartil: Q1

Madanat Y., Savona M.R., Sekeres M.A., Platzbecker U., Santini V., Fenaux P., Diez-Campelo M., Valcárcel D., Berry T., Dougherty S., Shah S., Sun L., Wan Y., Huang F., Navada S., Komrokji R.S., Zeidan A.M.. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs). Journal of the National Comprehensive Cancer Network : JNCCN. 5 April 2024. DOI: 10.6004/jnccn.2023.7228.

Impacto: 13.4. Cuartil: Q1 (1er decil)

Einsele H., Moreau P., Bahlis N., Bhutani M., Vincent L., Karlin L., Perrot A., Goldschmidt H., van de Donk N.W.C.J., Ocio E.M., Martinez-Lopez J., Rodríguez-Otero P., Dytfeld D., Diels J., Strulev V., Haddad I., Renaud T., Ammann E., Cabrieto J., Perualila N., Gan R., Zhang Y., Parekh T., Albrecht C., Weisel K., Mateos M.V.. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. Advances in Therapy. April 2024. DOI: 10.1007/s12325-024-02797-x.

Impacto: 3.8. Cuartil: Q2

Nooka A.K., Rodriguez C., Mateos M.V., Manier S., Chastain K., Banerjee A., Kobos R., Qi K., Verona R., Doyle M., Martin T.G., van de Donk N.W.C.J.. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 15 March 2024. DOI: 10.1002/cncr.35107.

Impacto: 6.2. Cuartil: Q1

Ocio E.M., Efebera Y.A., Hájek R., Straub J., Maisnar V., Eveillard J.R., Karlin L., Mateos M.V., Oriol A., Ribrag V., Richardson P.G., Norin S., Obermüller J., Bakker N.A., Pour L.. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica. 1 March 2024. DOI: 10.3324/haematol.2023.283490.

Cardona-Benavides I.J., Misiewicz-Krzeminska I., Rojas E.A., De Ramón C., Sanz-Solas A., Isidro I., Quwaider D., López-Guerrero A.M., Cuadrado M., Calasanz M.J., Rosiñol L., Martínez-López J., San Miguel J.F., Mateos M.V., Corchete L.A., Gutiérrez N.C.. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling. Haematologica. 1 March 2024. DOI: 10.3324/haematol.2023.283445.

Pour L., Szarejko M., Bila J., Schjesvold F.H., Spicka I., Maisnar V., Jurczyszyn A., Grudeva-Popova Z., Hájek R., Usenko G., Thuresson M., Norin S., Jarefors S., Bakker N.A., Richardson P.G., Mateos M.V.. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 1 March 2024. DOI: 10.3324/haematol.2023.283509.

Martin T.G., Moreau P., Usmani S.Z., Garfall A., Mateos M.V., San-Miguel J.F., Oriol A., Nooka A.K., Rosinol L., Chari A., Karlin L., Krishnan A., Bahlis N., Popat R., Besemer B., Martínez-López J., Delforge M., Trancucci D., Pei L., Kobos R., Fastenau J., Gries K.S., van de Donk N.W.C.J.. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. Clinical Lymphoma, Myeloma and Leukemia. March 2024. DOI: 10.1016/j.clml.2023.11.001.

Impacto: 2.7. Cuartil: Q3

Schjesvold F.H., Ludwig H., Mateos M.V., Larocca A., Abdulhaq H., Norin S., Thuresson M., Bakker N.A., Richardson P.G., Sonneveld P.. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study. European Journal of Haematology. March 2024. DOI: 10.1111/ejh.14127.

Impacto: 3.1. Cuartil: Q3

Greco R., Alexander T., Del Papa N., Müller F., Saccardi R., Sanchez-Guijo F., Schett G., Sharrack B., Snowden J.A., Tarte K., Onida F., Sánchez-Ortega I., Burman J., Castilla Llorente C., Cervera R., Ciceri F., Doria A., Henes J., Lindsay J., Mackensen A., Muraro P.A., Ricart E., Rovira M., Zuckerman T., Yakoub-Agha I., Farge D.. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine. March 2024. DOI: 10.1016/j.eclinm.2024.102476.

Rodríguez-García A., Arroyo A., García-Vicente R., Morales M.L., Gómez-Gordo R., Justo P., Cuéllar C., Sánchez-Pina J., López N., Alonso R., Puig N., Mateos M.V., Ayala R., Gómez-Garre D., Martínez-López J., Linares M.. Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma. Clinical Cancer Research. 15 February 2024. DOI: 10.1158/1078-0432.CCR-23-0195.

Impacto: 11.5. Cuartil: Q1 (1er decil)

Guerrero C., Puig N., Cedena M.T., Calasanz M.J., Gutierrez N.C., Fernandez M., Oriol A., Ríos-Tamayo R., Hernandez M.T., Martínez-Martínez R., Bargay J., de Arriba F., Palomera L., Gonzalez-Rodriguez A.P., Gonzalez Perez M.S., Orfao A., Mateos M.V., Martinez-Lopez J., Rosiñol L., Bladé J., Lahuerta J.J., San-Miguel J.F., Paiva B., Casanova Espinosa M., Zamudio J.L.G., Ríos Herranz E., Martín Sánchez J., Palomera Bernal L., González García M.E., Mayol A.S., Bargay Lleonart J., Suárez A., Hernández García M.T., Gaisán C.M., Hernández Ruiz B., Casado Montero F., Miguel Llorente D.d., Ramos F.S., Ibañez Garcia Á., Manteca M.M., Mariano Hernández Martín J., Escalante Barrigón F., García Frade J., de Coca A.G., Franco C.A., Labrador Gómez J., Cabezudo Pérez E., Bladé Creixentí J., Balari A.M.S., González Montes Y., Teigell L.E., García Guiñón A., Abella Monreal E., Alfonso Soler Campos J., Martí Tutusaus J.M., Rocafiguera A.O., Gorrochategui M.G., Mesa M.G., Silva C.C., Loureiro A.D., Méndez Sánchez J.A., Irazu M.J.N., Párraga F.J.P., Lahuerta Palacios J.J., Barahona P.B., Rodríguez C.E., Hernández Rivas J.Á., Oteyza J.P.d., Iglesias del Barrio R., López de la Guia A., Amor A.A., Prieto Pareja E., Castelló I.K., Blanchard Rodríguez M.J., Riaza Grau R., Mesa E.G., Ruiz Sainz E., Arriba F.d., Moraleda Jiménez J.M., Romera M., Cardoso F.P., Arguiñano Pérez J.M., Pomposo M.P., Pérez Persona E., Teruel Casasús A.I., García P.R., Jarque Ramos I., Villarrubia Lor M.B., Fernández García P.L., Martínez Chamorro C.. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 15 February 2024. DOI: 10.1182/blood.2023022083.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Ludwig H., Ramasamy K., Mateos M.V., Kishore B., Gergely V., Ladicka M., Ori A., Simoni L., Bent-Ennakhil N., Stull D.M., Gavini F., Terpos E., Hájek R.. Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting. Clinical Lymphoma, Myeloma and Leukemia. February 2024. DOI: 10.1016/j.clml.2023.10.003.

Impacto: 2.7. Cuartil: Q3

Montoro J., Boumendil A., Finel H., Bramanti S., Castagna L., Blaise D., Dominietto A., Kulagin A., Yakoub-Agha I., Tbakhi A., Solano C., Giebel S., Gulbas Z., López Corral L., Pérez-Simón J.A., Díez Martín J.L., Sanz J., Farina L., Koc Y., Socié G., Arat M., Jurado M., Bermudez A., Labussière-Wallet H., Villalba M., Ciceri F., Martinez C., Nagler A., Sureda A., Glass B.. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy. February 2024. DOI: 10.1016/j.jtct.2023.11.021.

Impacto: 3.2. Cuartil: Q2

Moreau P., Mateos M.V., Gonzalez Garcia M.E., Einsele H., De Stefano V., Karlin L., Lindsey-Hill J., Besemer B., Vincent L., Kirkpatrick S., Delforge M., Perrot A., van de Donk N.W.C.J., Pawlyn C., Manier S., Leleu X., Martinez-Lopez J., Ghilotti F., Diels J., Morano R., Albrecht C., Strulev V., Haddad I., Pei L., Kobos R., Smit J., Slavcev M., Marshall A., Weisel K.. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Advances in Therapy. February 2024. DOI: 10.1007/s12325-023-02738-0.

Impacto: 3.8. Cuartil: Q2

Spencer A., Moreau P., Mateos M.V., Goldschmidt H., Suzuki K., Levin M.D., Sonneveld P., Orlowski R.Z., Yoon S.S., Usmani S.Z., Weisel K., Reece D., Ahmadi T., Pei H., Mayo W.G., Gai X., Carey J., Bartlett J.B., Carson R., Dimopoulos M.A.. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Advances. 23 January 2024. DOI: 10.1182/bloodadvances.2023010579.

Impacto: 7.5. Cuartil: Q1

Platzbecker U., Santini V., Fenaux P., Sekeres M.A., Savona M.R., Madanat Y.F., Díez-Campelo M., Valcárcel D., Illmer T., Jonášová A., Bělohlávková P., Sherman L.J., Berry T., Dougherty S., Shah S., Xia Q., Sun L., Wan Y., Huang F., Ikin A., Navada S., Feller F., Komrokji R.S., Zeidan A.M.. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 20 January 2024. DOI: 10.1016/S0140-6736(23)01724-5.

Impacto: 168.9. Cuartil: Q1 (1er decil)

Iacoboni G., Navarro V., Martín-López A.Á., Rejeski K., Kwon M., Jalowiec K.A., Amat P., Reguera-Ortega J.L., Gallur L., Blumenberg V., Gutiérrez-Herrero S., Roddie C., Benzaquén A., Delgado-Serrano J., Sánchez-Salinas M.A., Bailén R., Carpio C., López-Corral L., Hernani R., Bastos M., O'Reilly M., Martín-Martín L., Subklewe M., Barba P.. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology. 10 January 2024. DOI: 10.1200/JCO.23.01097.

Impacto: 45.3. Cuartil: Q1 (1er decil)

Frerichs K.A., Verkleij C.P.M., Mateos M.V., Martin T.G., Rodriguez C., Nooka A., Banerjee A., Chastain K., Perales-Puchalt A., Stephenson T., Uhlar C., Kobos R., Van Der Holt B., Kruyswijk S., Kuipers M.T., Groen K., Vishwamitra D., Skerget S., Cortes-Selva D., Doyle M., Zaaijer H.L., Zweegman S., Verona R.I., Van De Donk N.W.C.J.. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Advances. 9 January 2024. DOI: 10.1182/bloodadvances.2023011658.

Impacto: 7.5. Cuartil: Q1

Penack O., Luft T., Peczynski C., Benner A., Sica S., Arat M., Itäla-Remes M., López Corral L., Schaap N.P.M., Karas M., Raida L., Schroeder T., Dreger P., Metafuni E., Ozcelik T., Sandmaier B.M., Kordelas L., Moiseev I., Schoemans H., Koenecke C., Basak G.W., Peric Z.. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study. Journal for ImmunoTherapy of Cancer. 9 January 2024. DOI: 10.1136/jitc-2023-007635.

Moser O., Ngoya M., Galimard J.E., Dalissier A., Dalle J.H., Kalwak K., Wössmann W., Burkhardt B., Bierings M., Gonzalez-Vicent M., López Corral L., Mellgren K., Attarbaschi A., Bourhis J.H., Carlson K., Corbacioglu S., Drabko K., Sundin M., Toporski J., Cario G., Kontny U.. Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study. Bone Marrow Transplantation. 2024. DOI: 10.1038/s41409-024-02226-1.

Impacto: 4.8. Cuartil: Q1

Torres-Esquius S., Beas F., Chen-Liang T.H., Pomares H., Santiago M., Varela N.D., Liquori A., Hernandez F., Xicoy B., Hermosín L., Arnan M., Tazón-Vega B., Blanco A., Cervera J., Diez-Campelo M., Lozano M.L., Valcárcel D., Bosch F., Montoro M.J., Jerez A.. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms. British Journal of Haematology. 2024. DOI: 10.1111/bjh.19460.

Impacto: 6.5. Cuartil: Q1

Mateos M.V., Weisel K., Diels J., Arribas A., Tamayo M., Schecter J.M., Roccia T., Haddad I., Pacaud L., Moreau P.. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study. Clinical Lymphoma, Myeloma and Leukemia. 2024. DOI: 10.1016/j.clml.2023.12.001.

Impacto: 2.7. Cuartil: Q3

Cabrero M., López-Corral L., Jarque I., de la Cruz-Vicente F., Pérez- López E., Valcárcel D., Sanz J., Espigado I., Ortí G., Martín- Calvo C., de la Serna J., Caballero D.. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial. Bone Marrow Transplantation. 2024. DOI: 10.1038/s41409-023-02171-5.

Impacto: 4.8. Cuartil: Q1

Quach H., Parmar G., Mateos M.V., Ailawadhi S., Leleu X.. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2024. DOI: 10.1016/j.clml.2024.02.004.

Impacto: 2.7. Cuartil: Q3

Sanchez-Guijo F., Vives J., Ruggeri A., Chabannon C., Corbacioglu S., Dolstra H., Farge D., Gagelmann N., Horgan C., Kuball J., Neven B., Rintala T., Rocha V., Sanchez-Ortega I., Snowden J.A., Zwaginga J.J., Gnecchi M., Sureda A.. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT). Cytotherapy. 2024. DOI: 10.1016/j.jcyt.2024.02.007.

Impacto: 4.5. Cuartil: Q2

Mosquera Orgueira A., Perez Encinas M.M., Diaz Varela N., Wang Y.H., Mora E., Diaz-Beya M., Montoro M.J., Pomares Marin H., Ramos Ortega F., Tormo M., Jerez A., Nomdedeu J., de Miguel Sanchez C., Arenillas L., Carcel P., Cedena Romero M.T., Xicoy Cirici B., Rivero Arango E., Del Orbe Barreto R.A., Benlloch L., Lin C.C., Tien H.F., Pérez Míguez C., Crucitti D., Díez Campelo M., Valcárcel D.. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification. British Journal of Haematology. 2024. DOI: 10.1111/bjh.19341.

Impacto: 6.5. Cuartil: Q1

Ortí G., Gras L., Koster L., Kulagin A., Byrne J., Apperley J.F., Halaburda K., Blau I.W., Clark A., Kröger N., Griskevicius L., Carlson K., Collin M., Bloor A., Raiola A.M., Blaise D., Aljurf M., López-Corral L., Sakellari I., Beguin Y., Wrobel T., de Rosa L., de Lavallade H., Hayden P.J., McLornan D., Chalandon Y., Yakoub-Agha I.. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT). Transplantation and Cellular Therapy. January 2024. DOI: 10.1016/j.jtct.2023.09.019.

Impacto: 3.2. Cuartil: Q2

Syrykh C., Pons-Brun B., Russiñol N., Playa-Albinyana H., Baumann T., Duran-Ferrer M., Kulis M., Carbó-Meix A., Mozas P., Alcoceba M., González M., Navarro-Bailón A., Colado E., Payer Á.R., Aymerich M., Terol M.J., Lu J., Knisbacher B.A., Hahn C.K., Ruiz-Gaspà S., Enjuanes A., Wu C.J., Getz G., Zenz T., López-Guillermo A., Martín-Subero J.I., Colomer D., Delgado J., Campo E., Nadeu F.. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Blood Advances. 12 December 2023. DOI: 10.1182/bloodadvances.2023010132.

Impacto: 7.5. Cuartil: Q1

Raje N., Mateos M.V., Iida S., Reece D.. Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-023-00804-y.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Gomez-Ruiz V., Blanco J.F., Villarón E.M., Fidalgo H., López-Parra M., Sánchez-Guijo F.. Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial. Stem Cell Research and Therapy. December 2023. DOI: 10.1186/s13287-023-03298-4.

Impacto: 7.5. Cuartil: Q1

Jiménez M.F., Gómez-Hernández M.T., Villarón E.M., López-Parra M., Sánchez-Guijo F.. Autologous mesenchymal stromal cells embedded with Tissucol Duo® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up. Stem Cell Research and Therapy. December 2023. DOI: 10.1186/s13287-023-03545-8.

Impacto: 7.5. Cuartil: Q1

Puertas B., González-Calle V., Sobejano-Fuertes E., Escalante F., Rey-Bua B., Padilla I., García-Sanz R., Puig N., Gutiérrez N.C., Mateos M.V.. Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-023-00807-9.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Moreau P., Chari A., Oriol A., Martinez-Lopez J., Haenel M., Touzeau C., Ailawadhi S., Besemer B., de la Rubia Comos J., Encinas C., Mateos M.V., Salwender H., Rodriguez-Otero P., Hulin C., Karlin L., Sureda Balari A., Bargay J., Benboubker L., Rosiñol L., Tarantolo S., Terebelo H., Yang S., Wang J., Nnane I., Qi M., Kosh M., Delioukina M., Goldschmidt H.. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-023-00805-x.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Impacto: 7.5. Cuartil: Q1

Bastos-Oreiro M., Gutierrez A., Iacoboni G., López Corral L., Reguera J.L., Abrisqueta P., Delgado J., Terol M.J., Hernani R., Martínez N., Ortíz V., Bailen R., Gomez-Centurión I., Caballero A., Sanz J., Guerra Domínguez L., Luzardo H., Mussetti A., Jiménez-Ubieto A., Sancho J.M., Sureda A., Pérez A., Barba P., Kwon M., Martín García-Sancho A.. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. Transplantation and Cellular Therapy. December 2023. DOI: 10.1016/j.jtct.2023.08.026.

Impacto: 3.2. Cuartil: Q2

Botta C., Perez C., Larrayoz M., Puig N., Cedena M.T., Termini R., Goicoechea I., Rodriguez S., Zabaleta A., Lopez A., Sarvide S., Blanco L., Papetti D.M., Nobile M.S., Besozzi D., Gentile M., Correale P., Siragusa S., Oriol A., González-Garcia M.E., Sureda A., de Arriba F., Rios Tamayo R., Moraleda J.M., Gironella M., Hernandez M.T., Bargay J., Palomera L., Pérez-Montaña A., Goldschmidt H., Avet-Loiseau H., Roccaro A., Orfao A., Martinez-Lopez J., Rosiñol L., Lahuerta J.J., Blade J., Mateos M.V., San-Miguel J.F., Martinez Climent J.A., Paiva B.. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance. Nature Communications. December 2023. DOI: 10.1038/s41467-023-41562-6.

Piñana J.L., Vazquez L., Calabuig M., López-Corral L., Martin-Martin G., Villalon L., Sanz-Linares G., Conesa-Garcia V., Sanchez-Salinas A., Gago B., Facal A., Risco-Gálvez I., Olave M.T., Espigado I., Lopez-Jimenez J., Hernández-Rivas J.Á., Avendaño-Pita A., Arroyo I., Ferrer E., García-Cadenas I., González-Santillana C., Roldán-Pérez A., Ferrer B., Guerreiro M., Suarez-Lledó M., Camara A., Campos-Beltrán D., Navarro D., Cedillo Á., Sureda A., Solano C., Martino R.. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-022-00778-3.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Raje N., Anderson K., Einsele H., Efebera Y., Gay F., Hammond S.P., Lesokhin A.M., Lonial S., Ludwig H., Moreau P., Patel K., Ramasamy K., Mateos M.V.. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-023-00879-7.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Mateos M.V., Ailawadhi S., Costa L.J., Grant S.J., Kumar L., Mohty M., Aydin D., Usmani S.Z.. Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-023-00877-9.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Raje N., Mateos M.V., Iida S., Reece D.. Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy (Blood Cancer Journal, (2023), 13, 1, (41), 10.1038/s41408-023-00804-y). Blood Cancer Journal. December 2023. DOI: 10.1038/s41408-023-00866-y.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Impacto: 7.5. Cuartil: Q1

Rosiñol L., Oriol A., Ríos R., Blanchard M.J., Jarque I., Bargay J., Hernández M.T., Cabañas V., Carrillo-Cruz E., Sureda A., Martínez-López J., Krsnik I., González M.E., Casado L.F., Martí J.M., Encinas C., de Arriba F., Palomera L., Sampol A., González-Montes Y., Cabezudo E., Paiva B., Puig N., Cedena M.T., de la Cruz J., Mateos M.V., San Miguel J., Lahuerta J.J., Bladé J.. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2 November 2023. DOI: 10.1182/blood.2022019531.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Chatzikonstantinou T., Scarfò L., Karakatsoulis G., Minga E., Chamou D., Iacoboni G., Kotaskova J., Demosthenous C., Smolej L., Mulligan S., Alcoceba M., Al-Shemari S., Aurran-Schleinitz T., Bacchiarri F., Bellido M., Bijou F., Calleja A., Medina A., Khan M.A., Cassin R., Chatzileontiadou S., Collado R., Christian A., Davis Z., Dimou M., Donaldson D., Santos G.D., Dreta B., Efstathopoulou M., El-Ashwah S., Enrico A., Fresa A., Galimberti S., Galitzia A., García-Serra R., Gimeno E., González-Gascón-y-Marín I., Gozzetti A., Guarente V., Guieze R., Gogia A., Gupta R., Harrop S., Hatzimichael E., Herishanu Y., Hernández-Rivas J.Á., Inchiappa L., Jaksic O., Janssen S., Kalicińska E., Kamel L., Karakus V., Kater A.P., Kho B., Kislova M., Konstantinou E., Koren-Michowitz M., Kotsianidis I., Kreitman R.J., Labrador J., Lad D., Levin M.D., Levy I., Longval T., Lopez-Garcia A., Marquet J., Martin-Rodríguez L., Maynadié M., Maslejova S., Mayor-Bastida C., Mihaljevic B., Milosevic I., Miras F., Moia R., Morawska M., Murru R., Nath U.K., Navarro-Bailón A., Oliveira A.C., Olivieri J., Oscier D., Panovska-Stavridis I., Papaioannou M., Papajík T., Kubova Z., Phumphukhieo P., Pierie C., Puiggros A., Rani L., Reda G., Rigolin G.M., Ruchlemer R., Daniel de Deus Santos M., Schipani M., Schiwitza A., Shen Y., Simkovic M., Smirnova S., Abdelrahman Soliman D.S., Spacek M.. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. eClinicalMedicine. November 2023. DOI: 10.1016/j.eclinm.2023.102307.

Rejeski K., Wang Y., Albanyan O., Munoz J., Sesques P., Iacoboni G., Lopez-Corral L., Ries I., Bücklein V.L., Mohty R., Dreyling M., Baluch A., Shah B., Locke F.L., Hess G., Barba P., Bachy E., Lin Y., Subklewe M., Jain M.D.. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American Journal of Hematology. November 2023. DOI: 10.1002/ajh.27056.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Richardson P.G., Durie B.G., Rosiñol L., Mateos M.V., Dispenzieri A., Moreau P., Kumar S., Raje N., Munshi N., Laubach J.P., O’Gorman P., O’Donnell E., Voorhees P., Facon T., Bladé J., Lonial S., Perrot A., Anderson K.C.. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica. November 2023. DOI: 10.3324/haematol.2022.282624.

Impacto: 10.1. Cuartil: Q1 (1er decil)

Curigliano G., Di Stefano A.L., Sanson M., Sanz M.A., Mateos M.V.. Editorial introductions. Current Opinion in Oncology. 1 November 2023. DOI: 10.1097/CCO.0000000000001001.

Impacto: 3.4. Cuartil: Q3

Preciado S., Martínez-Villaluenga C., Rico D., Muntión S., García-Macías M.C., Navarro-Bailón A., Martín-Diana A.B., Sánchez-Guijo F.. Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease. Nutrients. November 2023. DOI: 10.3390/nu15214582.

Impacto: 5.9. Cuartil: Q1

García-Vílchez R., Añazco-Guenkova A.M., López J., Dietmann S., Tomé M., Jimeno S., Azkargorta M., Elortza F., Bárcena L., Gonzalez-Lopez M., Aransay A.M., Sánchez-Martín M.A., Huertas P., Durán R.V., Blanco S.. N7-methylguanosine methylation of tRNAs regulates survival to stress in cancer. Oncogene. 20 October 2023. DOI: 10.1038/s41388-023-02825-0.

Impacto: 8.0. Cuartil: Q1 (1er decil)

Rodríguez-Arbolí E., Lee C.J., Caballero-Velázquez T., Martínez C., García-Calderón C., Jiménez-León M.R., Bermúdez-Rodríguez M.A., López-Corral L., Triguero A., Onstad L., Horwitz M.E., Sarantopoulos S., Lee S.J., Pérez-Simón J.A.. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials. Clinical Cancer Research. 15 October 2023. DOI: 10.1158/1078-0432.CCR-23-0666.

Impacto: 11.5. Cuartil: Q1 (1er decil)

Mosquera Orgueira A., Perez Encinas M.M., Diaz Varela N.A., Mora E., Díaz-Beyá M., Montoro M.J., Pomares H., Ramos F., Tormo M., Jerez A., Nomdedeu J.F., De Miguel Sanchez C., Leonor A., Cárcel P., Cedena Romero M.T., Xicoy B., Rivero E., Del Orbe Barreto R.A., Diez-Campelo M., Benlloch L.E., Crucitti D., Valcárcel D.. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes. HemaSphere. 11 October 2023. DOI: 10.1097/HS9.0000000000000961.

Impacto: 6.6. Cuartil: Q1

Dimopoulos M.A., Terpos E., Boccadoro M., Delimpasi S., Beksac M., Katodritou E., Moreau P., Baldini L., Symeonidis A., Bila J., Oriol A., Mateos M.V., Einsele H., Orfanidis I., Kampfenkel T., Liu W., Wang J., Kosh M., Tran N.P., Carson R., Sonneveld P.. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. The Lancet Haematology. October 2023. DOI: 10.1016/S2352-3026(23)00218-1.

Impacto: 24.7. Cuartil: Q1 (1er decil)

Vives J., Sánchez-Guijo F., Gnecchi M., Zwaginga J.J.. Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe. Cytotherapy. October 2023. DOI: 10.1016/j.jcyt.2023.06.006.

Impacto: 4.5. Cuartil: Q2

Piñana J.L., Heras I., Aiello T.F., García-Cadenas I., Vazquez L., Lopez-Jimenez J., Chorão P., Aroca C., García-Vidal C., Arroyo I., Soler-Espejo E., López-Corral L., Avendaño-Pita A., Arrufat A., Garcia-Gutierrez V., Arellano E., Hernández-Medina L., González-Santillana C., Morell J., Hernández-Rivas J.Á., Rodriguez-Galvez P., Mico-Cerdá M., Guerreiro M., Campos D., Navarro D., Cedillo Á., Martino R., Solano C.. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. October 2023. DOI: 10.3390/v15102066.

Puertas B., González-Calle V., Sureda A., Moreno M.J., Oriol A., González E., Rosiñol L., López J., Escalante F., Martínez-Lopez J., Carrillo E., Clavero E., Ríos-Tamayo R., Rey-Bua B., González-Rodríguez A.P., Dourdil V., de Arriba F., González S., Pérez-De-Oteyza J., Hernández M.T., García-Mateo A., Bargay J., Bladé J., Lahuerta J.J., San Miguel J.F., Ocio E.M., Mateos M.V.. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica. October 2023. DOI: 10.3324/haematol.2022.282490.

Impacto: 10.1. Cuartil: Q1 (1er decil)

Ramasamy K., Avet-Loiseau H., Hveding Blimark C., Delforge M., Gay F., Manier S., Martinez-Lopez J., Mateos M.V., Mohty M., Van De Donk N.W.C.J., Weisel K.. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study. HemaSphere. 30 September 2023. DOI: 10.1097/HS9.0000000000000942.

Impacto: 6.6. Cuartil: Q1

Alejo E., Puertas B., Mateos M.V.. Monoclonal gammopathy of uncertain significance. Medicina Clinica. 8 September 2023. DOI: 10.1016/j.medcli.2023.05.006.

Impacto: 3.9. Cuartil: Q2

Rejeski K., Subklewe M., Aljurf M., Bachy E., Balduzzi A., Barba P., Bruno B., Benjamin R., Carrabba M.G., Chabannon C., Ciceri F., Corradini P., Delgado J., Di Blasi R., Greco R., Houot R., Iacoboni G., Jäger U., Kersten M.J., Mielke S., Nagler A., Onida F., Peric Z., Roddie C., Ruggeri A., Sánchez-Guijo F., Sánchez-Ortega I., Schneidawind D., Schubert M.L., Snowden J.A., Thieblemont C., Topp M., Zinzani P.L., Gribben J.G., Bonini C., Sureda A., Yakoub-Agha I.. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 7 September 2023. DOI: 10.1182/blood.2023020578.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Chari A., Askari E., Caers J., Costa L.J., Hilder B.W., Krishnan A., Mateos M.V., Minnema M.C., Oriol A., Pillarisetti K., Van De Donk N.W.C.J., Rodríguez-Otero P.. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. Future Oncology. 1 September 2023. DOI: 10.2217/fon-2023-0332.

Impacto: 3.3. Cuartil: Q3

Sonneveld P., Richardson P.G., Ludwig H., Dimopoulos M.A., Schjesvold F.H., Hájek R., Abdulhaq H., Thuresson M., Norin S., Bakker N.A., Mateos M.V.. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies. Clinical Lymphoma, Myeloma and Leukemia. September 2023. DOI: 10.1016/j.clml.2023.05.004.

Impacto: 2.7. Cuartil: Q3

Oliver-Caldés A., González-Calle V., Cabañas V., Español-Rego M., Rodríguez-Otero P., Reguera J.L., López-Corral L., Martin-Antonio B., Zabaleta A., Inogés S., Varea S., Rosiñol L., López-Díaz de Cerio A., Tovar N., Jiménez R., López-Parra M., Rodríguez-Lobato L.G., Sánchez-Salinas A., Olesti E., Calvo-Orteu M., Delgado J., Pérez-Simón J.A., Paiva B., Prósper F., Sáez-Peñataro J., Juan M., Moraleda J.M., Mateos M.V., Pascal M., Urbano-Ispizua A., Fernández de Larrea C.. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. The Lancet Oncology. August 2023. DOI: 10.1016/S1470-2045(23)00222-X.

Impacto: 51.1. Cuartil: Q1 (1er decil)

Toribio-Castelló S., Castaño S., Villaverde-Ramiro Á., Such E., Arnán M., Solé F., Díaz-Beyá M., Díez-Campelo M., del Rey M., González T., Hernández-Rivas J.M.. Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8. Cancers. August 2023. DOI: 10.3390/cancers15153822.

Impacto: 5.2. Cuartil: Q2

Castillo M.I., Ribate V.E., Muñoz C.M., Santillana S.G., Taboada S.E., Casterá M.E., Abinzano C.M.J., Barranco I.A., Nieto C.R., Pampliega V.M., Blanco M.L., de Andrés Á.S., de Oteyza P.J., del Castillo B.T., Font G.I., Cayuela J.A., Díez-Campelo M., Sánchez A.R., Vercet S.C., Díaz T.M.. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion. Cancer Medicine. August 2023. DOI: 10.1002/cam4.6300.

Impacto: 4.0. Cuartil: Q2

Mateos M.V., Weisel K., Martin T., Berdeja J.G., Jakubowiak A., Stewart A.K., Jagannath S., Lin Y., Diels J., Ghilotti F., Thilakarathne P., Perualila N.J., Cabrieto J., Haefliger B., Erler-Yates N., Hague C., Jackson C.C., Schecter J.M., Strulev V., Nesheiwat T., Pacaud L., Einsele H., Moreau P.. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. August 2023. DOI: 10.3324/haematol.2022.280482.

Impacto: 10.1. Cuartil: Q1 (1er decil)

Solano C., Castro-Rebollo P., Pérez-Martínez A., López-Corral L., Barba-Suñol P., Kwon M., Ortiz V., Sanz-Caballer J., Caballero A.C., Martínez J., Cedillo Á., Sureda A.. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: A survey-based study. BMJ Open. 25 July 2023. DOI: 10.1136/bmjopen-2022-071371.

Impacto: 2.9. Cuartil: Q2

Usmani S.Z., Quach H., Mateos M.V., Landgren O., Leleu X., Siegel D., Weisel K., Shu X., Li C., Dimopoulos M.. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Advances. 25 July 2023. DOI: 10.1182/bloodadvances.2023010026.

Impacto: 7.5. Cuartil: Q1

Ocio E.M., Perrot A., Bories P., San-Miguel J.F., Blau I.W., Karlin L., Martinez-Lopez J., Wang S.Y., Bringhen S., Marcatti M., Mateos M.V., Rodriguez-Otero P., Oliva S., Nogai A., Le Roux N., Dong L., Macé S., Gassiot M., Fitzmaurice T., Oprea C., Moreau P.. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. Leukemia. July 2023. DOI: 10.1038/s41375-023-01936-7.

Impacto: 11.4. Cuartil: Q1 (1er decil)

Martin T.G., Mateos M.V., Nooka A., Banerjee A., Kobos R., Pei L., Qi M., Verona R., Doyle M., Smit J., Sun W., Trancucci D., Uhlar C., van de Donk N.W.C.J., Rodriguez C.. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer. 1 July 2023. DOI: 10.1002/cncr.34756.

Impacto: 6.2. Cuartil: Q1

Mateos M.V., Rigaudeau S., Basu S., Spicka I., Schots R., Wrobel T., Cook G., Beksac M., Gries K.S., Kudva A., Tromp B., Van Rampelbergh R., Pei H., Wroblewski S., Carson R., Delioukina M., White D.. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. Journal of Oncology Pharmacy Practice. July 2023. DOI: 10.1177/10781552221103551.

Impacto: 1.3. Cuartil: Q4

Dimopoulos M.A., Merlini G., Bridoux F., Leung N., Mikhael J., Harrison S.J., Kastritis E., Garderet L., Gozzetti A., van de Donk N.W.C.J., Weisel K.C., Badros A.Z., Beksac M., Hillengass J., Mohty M., Ho P.J., Ntanasis-Stathopoulos I., Mateos M.V., Richardson P., Blade J., Moreau P., San-Miguel J., Munshi N., Rajkumar S.V., Durie B.G.M., Ludwig H., Terpos E.. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. The Lancet Oncology. July 2023. DOI: 10.1016/S1470-2045(23)00223-1.

Impacto: 51.1. Cuartil: Q1 (1er decil)

Bejarano L., Sayagués J.M., Alcoceba M., Balanzategui A., Lopez-Corral L., Cañueto J., Santos-Briz A.. Primary Cutaneous Marginal Zone Lymphoproliferative Disorder of Donor Origin after Allogeneic Hematopoietic Stem Cell Transplantation. American Journal of Dermatopathology. 1 June 2023. DOI: 10.1097/DAD.0000000000002439.

Impacto: 1.1. Cuartil: Q4

Burgos L., Tamariz-Amador L.E., Puig N., Cedena M.T., Guerrero C., Jelínek T., Johnson S., Milani P., Cordon L., Perez J.J., Lasa M., Termini R., Oriol A., Hernandez M.T., Palomera L., Martinez-Martinez R., De La Rubia J., De Arriba F., Rios R., Gonzalez M.E., Gironella M., Cabañas V., Casanova M., Krsnik I., Perez-Montaña A., González-Calle V., Rodriguez-Otero P., Maisnar V., Hajek R., Van Rhee F., Jimenez-Zepeda V., Palladini G., Merlini G., Orfao A., De La Cruz J., Martinez-Lopez J., Lahuerta J.J., Rosiñol L., Blade J., Mateos M.V., San-Miguel J.F., Paiva B.. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. Journal of Clinical Oncology. 1 June 2023. DOI: 10.1200/JCO.22.01916.

Impacto: 45.3. Cuartil: Q1 (1er decil)

Ludwig H., Terpos E., van de Donk N., Mateos M.V., Moreau P., Dimopoulos M.A., Delforge M., Rodriguez-Otero P., San-Miguel J., Yong K., Gay F., Einsele H., Mina R., Caers J., Driessen C., Musto P., Zweegman S., Engelhardt M., Cook G., Weisel K., Broijl A., Beksac M., Bila J., Schjesvold F., Cavo M., Hajek R., Touzeau C., Boccadoro M., Sonneveld P.. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology. June 2023. DOI: 10.1016/S1470-2045(23)00159-6.

Impacto: 51.1. Cuartil: Q1 (1er decil)

Saccardi R., Putter H., Eikema D.J., Busto M.P., McGrath E., Middelkoop B., Adams G., Atlija M., Ayuk F.A., Baldomero H., Beguin Y., de la Cámara R., Cedillo Á., Balari A.M.S., Chabannon C., Corbacioglu S., Dolstra H., Duarte R.F., Dulery R., Greco R., Gusi A., Hamad N., Kenyon M., Kröger N., Labopin M., Lee J., Ljungman P., Manson L., Mensil F., Milpied N., Mohty M., Oldani E., Orchard K., Passweg J., Pearce R., de Latour R.P., Poirel H.A., Rintala T., Rizzo J.D., Ruggeri A., Sanchez-Martinez C., Sanchez-Guijo F., Sánchez-Ortega I., Trnková M., Ferreiras D.V., Wilcox L., de Wreede L.C., Snowden J.A.. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation. June 2023. DOI: 10.1038/s41409-023-01924-6.

Impacto: 4.8. Cuartil: Q1

D'Amico S., Dall'Olio D., Sala C., Dall'Olio L., Sauta E., Zampini M., Asti G., Lanino L., Maggioni G., Campagna A., Ubezio M., Russo A., Bicchieri M.E., Riva E., Tentori C.A., Travaglino E., Morandini P., Savevski V., Santoro A., Prada-Luengo I., Krogh A., Santini V., Kordasti S., Platzbecker U., Diez-Campelo M., Fenaux P., Haferlach T., Castellani G., Della Porta M.G.. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology. JCO clinical cancer informatics. 1 June 2023. DOI: 10.1200/CCI.23.00021.

Sauta E., Robin M., Bersanelli M., Travaglino E., Meggendorfer M., Zhao L.P., Caballero Berrocal J.C., Sala C., Maggioni G., Bernardi M., Di Grazia C., Vago L., Rivoli G., Borin L., D'Amico S., Tentori C.A., Ubezio M., Campagna A., Russo A., Mannina D., Lanino L., Chiusolo P., Giaccone L., Voso M.T., Riva M., Oliva E.N., Zampini M., Riva E., Nibourel O., Bicchieri M., Bolli N., Rambaldi A., Passamonti F., Savevski V., Santoro A., Germing U., Kordasti S., Santini V., Diez-Campelo M., Sanz G., Sole F., Kern W., Platzbecker U., Ades L., Fenaux P., Haferlach T., Castellani G., Della Porta M.G.. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Journal of Clinical Oncology. 20 May 2023. DOI: 10.1200/JCO.22.01784.

Impacto: 45.3. Cuartil: Q1 (1er decil)

Piñana J.L., Martino R., Vazquez L., López-Corral L., Pérez A., Chorão P., Avendaño-Pita A., Pascual M.J., Sánchez-Salinas A., Sanz-Linares G., Olave M.T., Arroyo I., Tormo M., Villalon L., Conesa-Garcia V., Gago B., Terol M.J., Villalba M., Garcia-Gutierrez V., Cabero A., Hernández-Rivas J.Á., Ferrer E., García-Cadenas I., Teruel A., Navarro D., Cedillo Á., Sureda A., Solano C.. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplantation. May 2023. DOI: 10.1038/s41409-023-01946-0.

Impacto: 4.8. Cuartil: Q1

Hidalgo Calleja C., Sánchez González M.D., Medina Luezas J., López Corral L.. Chronic graft-versus-recipient disease: systematic review of joint and fascial involvement. Reumatologia Clinica. May 2023. DOI: 10.1016/j.reuma.2022.12.002.

Mateos M.V., Chari A., Usmani S.Z., Goldschmidt H., Weisel K., Qi K., Londhe A., Nair S., Lin X., Pei L., Ammann E., Kobos R., Smit J., Parekh T., Marshall A., Slavcev M., Moreau P.. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. May 2023. DOI: 10.1016/j.clml.2023.02.006.

Impacto: 2.7. Cuartil: Q3

Moreau P., van de Donk N.W.C.J., Delforge M., Einsele H., De Stefano V., Perrot A., Besemer B., Pawlyn C., Karlin L., Manier S., Leleu X., Weisel K., Ghilotti F., Diels J., Elsada A., Morano R., Strulev V., Pei L., Kobos R., Smit J., Slavcev M., Mateos M.V.. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. Advances in Therapy. May 2023. DOI: 10.1007/s12325-023-02480-7.

Impacto: 3.8. Cuartil: Q2

Zeidan A.M., Platzbecker U., Bewersdorf J.P., Stahl M., Adès L., Borate U., Bowen D., Buckstein R., Brunner A., Carraway H.E., Daver N., Díez-Campelo M., de Witte T., DeZern A.E., Efficace F., Garcia-Manero G., Garcia J.S., Germing U., Giagounidis A., Griffiths E.A., Hasserjian R.P., Hellström-Lindberg E., Iastrebner M., Komrokji R., Kulasekararaj A.G., Malcovati L., Miyazaki Y., Odenike O., Santini V., Sanz G., Scheinberg P., Stauder R., van de Loosdrecht A.A., Wei A.H., Sekeres M.A., Fenaux P.. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 27 April 2023. DOI: 10.1182/blood.2022018604.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Penack O., Peczynski C., Koenecke C., Polge E., Kuhnl A., Fegueux N., Daskalakis M., Kröger N., Dreger P., Besley C., Schanz U., Bloor A., Ganser A., Forcade E., López Corral L., Passweg J.R., Novak U., Moiseev I., Schoemans H., Basak G.W., Chabannon C., Sureda A., Averbuch D., Glass B., De La Camara R., Peric Z.. Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer. 18 April 2023. DOI: 10.1136/jitc-2022-006406.

Mateos M.V., González-Calle V.. Lenalidomide maintenance based on a genetic profile. Blood. 6 April 2023. DOI: 10.1182/blood.2022019352.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Rejeski K., Blumenberg V., Iacoboni G., Lopez-Corral L., Kharboutli S., Hernani R., Petrera A., Müller N., Hildebrand F., Frölich L., Karschnia P., Schmidt C., Cordas Dos Santos D.M., Piñana J.L., Müller F., Martin A.A., Dreyling M., Von Bergwelt-Baildon M., Barba P., Subklewe M., Bücklein V.L.. Identifying Early Infections in the Setting of CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. HemaSphere. 5 April 2023. DOI: 10.1097/HS9.0000000000000858.

Impacto: 6.6. Cuartil: Q1

Moreau P., Van De Donk N.W.C.J., Nahi H., Oriol A., Nooka A.K., Martin T., Rosinol L., Karlin L., Benboubker L., Mateos M.V., Popat R., Martínez-López J., Sidana S., Delforge M., Pei L., Trancucci D., Olyslager Y., Uhlar C., Stephenson T., Rampelbergh R.V., Banerjee A., Kobos R., Usmani S.Z.. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma. Future Oncology. 1 April 2023. DOI: 10.2217/fon-2023-0171.

Impacto: 3.3. Cuartil: Q3

Sonneveld P., Chanan-Khan A., Weisel K., Nooka A.K., Masszi T., Beksac M., Spicka I., Hungria V., Munder M., Mateos M.V., Mark T.M., Levin M.D., Ahmadi T., Qin X., Garvin Mayo W., Gai X., Carey J., Carson R., Spencer A.. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 10 March 2023. DOI: 10.1200/JCO.21.02734.

Impacto: 45.3. Cuartil: Q1 (1er decil)

Jelinek T., Bezdekova R., Zihala D., Sevcikova T., Sithara A.A., Pospisilova L., Sevcikova S., Polackova P., Stork M., Knechtova Z., Venglar O., Kapustova V., Popkova T., Muronova L., Chyra Z., Hrdinka M., Simicek M., Garcés J.J., Puig N., Cedena M.T., Jurczyszyn A., Castillo J.J., Penka M., Radocha J., Mateos M.V., San-Miguel J.F., Paiva B., Pour L., Rihova L., Hajek R.. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. Journal of Clinical Oncology. 1 March 2023. DOI: 10.1200/JCO.22.01226.

Impacto: 45.3. Cuartil: Q1 (1er decil)

Blanco J.F., Garcia-Garcia F.J., Villarón E.M., da Casa C., Fidalgo H., López-Parra M., Santos J.A., Sánchez-Guijo F.. Long-Term Results of a Phase I/II Clinical Trial of Autologous Mesenchymal Stem Cell Therapy for Femoral Head Osteonecrosis. Journal of Clinical Medicine. March 2023. DOI: 10.3390/jcm12062117.

Impacto: 3.9. Cuartil: Q2

Puertas B., González-Calle V., Sobejano-Fuertes E., Escalante F., Queizán J.A., Bárez A., Labrador J., Alonso-Alonso J.M., García de Coca A., Cantalapiedra A., Villaescusa T., Aguilar-Franco C., Alejo-Alonso E., Rey-Bua B., López-Corral L., García-Sanz R., Puig N., Gutiérrez N.C., Mateos M.V.. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers. March 2023. DOI: 10.3390/cancers15051558.

Impacto: 5.2. Cuartil: Q2

Paiva B., Manrique I., Dimopoulos M.A., Gay F., Min C.K., Zweegman S., Špička I., Teipel R., Mateos M.V., Giuliani N., Cavo M., Hopkins C.R., Fu W., Suryanarayan K., Vorog A., Li C., Wang B., Estevam J., Labotka R., Dash A.B.. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 9 February 2023. DOI: 10.1182/blood.2022016782.

Impacto: 20.3. Cuartil: Q1 (1er decil)

Germing U., Fenaux P., Platzbecker U., Buckstein R., Santini V., Díez-Campelo M., Yucel A., Tang D., Fabre S., Zhang G., Zoffoli R., Ha X., Miteva D., Hughes C., Komrokji R.S., Zeidan A.M., Garcia-Manero G.. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. Annals of Hematology. February 2023. DOI: 10.1007/s00277-022-05071-8.

Impacto: 3.5. Cuartil: Q2

Dawson M.A., Borthakur G., Huntly B.J.P., Karadimitris A., Alegre A., Chaidos A., Vogl D.T., Pollyea D.A., Davies F.E., Morgan G.J., Glass J.L., Kamdar M., Mateos M.V., Tovar N., Yeh P., Delgado R.G., Basheer F., Marando L., Gallipoli P., Wyce A., Krishnatry A.S., Barbash O., Bakirtzi E., Ferron-Brady G., Karpinich N.O., McCabe M.T., Foley S.W., Horner T., Dhar A., Kremer B.E., Dickinson M.. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research. 1 February 2023. DOI: 10.1158/1078-0432.CCR-22-1284.

Impacto: 11.5. Cuartil: Q1 (1er decil)

Landeira-Viñuela A., Alcoceba-Sanchez M., Navarro-Bailón A., Arias-Hidalgo C., Juanes-Velasco P., Sánchez-Santos J.M., Lecrevisse Q., Pedreira C.E., García-Vaquero M.L., Hernández Á.P., Montalvillo E., Góngora R., De las Rivas J., González-Díaz M., Orfao A., Fuentes M.. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution. Cancers. February 2023. DOI: 10.3390/cancers15030891.

Impacto: 5.2. Cuartil: Q2

Ocio E.M., Bringhen S., Martinez-Lopez J., San-Miguel J., Oliva S., Rodriguez-Otero P., Le Roux N., Dong Y., Doroumian S., Macé S., Mateos M.V.. Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients. HemaSphere. 1 February 2023. DOI: 10.1097/HS9.0000000000000829.

Impacto: 6.6. Cuartil: Q1

Maggioni G., Bersanelli M., Travaglino E., Alfonso Piérola A., Kasprzak A., Sangerman Montserrat A., Sauta E., Sala C., Matteuzzi T., Meggendorfer M., Gnocchi M., Zhao L.P., Tentori C.A., Nachtkamp K., Dall'Olio D., Mosca E., Ubezio M., Campagna A., Russo A., Rivoli G., Bernardi M., Borin L., Voso M.T., Riva M., Oliva E., Zampini M., Riva E., Saba E., D'Amico S., Lanino L., Tinterri B., Re F., Bicchieri M., Giordano L., Angelotti G., Morandini P., Kubasch A.S., Passamonti F., Rambaldi A., Savevski V., Santoro A., van de Loosdrecht A.A., Brogi A., Santini V., Kordasti S., Sanz G., Sole F., Gattermann N., Kern W., Platzbecker U., Ades L., Fenaux P., Haferlach T., Castellani G., Germing U., Diez-Campelo M., Della Porta M.G.. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. The Lancet Haematology. February 2023. DOI: 10.1016/S2352-3026(22)00323-4.

Impacto: 24.7. Cuartil: Q1 (1er decil)

Mateos M.V., Prosper F., Martin Sánchez J., Ocio E.M., Oriol A., Motlló C., Michot J.M., Jarque I., Iglesias R., Solé M., Martínez S., Kahatt C., Fudio S., Corral G., Zeaiter A., Montilla L., Ribrag V.. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Cancer Medicine. February 2023. DOI: 10.1002/cam4.5250.

Impacto: 4.0. Cuartil: Q2

Clavaín L., Fernández-Pisonero I., Movilla N., Lorenzo-Martín L.F., Nieto B., Abad A., García-Navas R., Llorente-González C., Sánchez-Martín M., Vicente-Manzanares M., Santos E., Alarcón B., García-Aznar J.M., Dosil M., Bustelo X.R.. Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors. Oncogene. 27 January 2023. DOI: 10.1038/s41388-022-02563-9.

Impacto: 8.0. Cuartil: Q1 (1er decil)

Cohen A.D., Mateos M.V., Cohen Y.C., Rodriguez-Otero P., Paiva B., van de Donk N.W.C.J., Martin T., Suvannasankha A., De Braganca K.C., Corsale C., Schecter J.M., Varsos H., Deraedt W., Wang L., Vogel M., Roccia T., Xu X., Mistry P., Zudaire E., Akram M., Nesheiwat T., Pacaud L., Avivi I., San-Miguel J.. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 19 January 2023. DOI: 10.1182/blood.2022015526.

Impacto: 20.3. Cuartil: Q1 (1er decil)